Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bonyf NVXPAR:MLBON 12 Return-on-Tangible-Equity is -1.39% as of Dec. 2024. GuruFocus rates XPAR:MLBON with a GF Score™ of 12/100 and a GF Value™ of €8.61 (Possible Value Trap). The stock has 2 warning signs investors should review. Among 759 Medical Devices & Instruments companies, Bonyf NV ranks worse than 59.55% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Bonyf NV's annualized net income for the quarter that ended in Dec. 2024 was €-0.04 Mil. Bonyf NV's average shareholder tangible equity for the quarter that ended in Dec. 2024 was €2.66 Mil. Therefore, Bonyf NV's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2024 was -1.39%.
The historical rank and industry rank for Bonyf NV's Return-on-Tangible-Equity or its related term are showing as below:
XPAR:MLBON'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -168.94 Med: -30.7 Max: 75.2
Current: -1.39
During the past 5 years, Bonyf NV's highest Return-on-Tangible-Equity was 75.20%. The lowest was -168.94%. And the median was -30.70%.
XPAR:MLBON's Return-on-Tangible-Equity is ranked worse than 59.55% of 759
companies
in the Medical Devices & Instruments industry
Industry Median: 4.02
vs XPAR:MLBON: -1.39
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Bonyf NV Return-on-Tangible-Equity Related Terms
Bonyf NV Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Bonyf NV's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bonyf NV Return-on-Tangible-Equity Chart
Bonyf NV Annual Data
Trend
Dec19
Dec20
Dec22
Dec23
Dec24
Return-on-Tangible-Equity
75.20
-30.70
-168.94
-32.62
-1.39
Bonyf NV Semi-Annual Data
Dec19
Dec20
Dec22
Dec23
Dec24
Return-on-Tangible-Equity
75.20
-30.70
-168.94
-32.62
-1.39
XPAR:MLBON vs ISRG, BDX, MDLN: Return-on-Tangible-Equity Comparison
For the Medical Instruments & Supplies subindustry, Bonyf NV's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bonyf NV Return-on-Tangible-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Bonyf NV's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Bonyf NV's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is one times the annual (Dec. 2024) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of -1.39% mean?
Bonyf NV (XPAR:MLBON) has a Return-on-Tangible-Equity of -1.39% as of Dec. 2024. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Bonyf NV and its competitors. According to the industry distribution chart, Bonyf NV ranks #452 out of 759 companies in the Medical Devices & Instruments industry, placing it in the top 59.6%.
Is Bonyf NV's Return-on-Tangible-Equity too high?
Bonyf NV's current Return-on-Tangible-Equity is -1.39%. Based on the distribution chart, Bonyf NV ranks #452 out of 759 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Bonyf NV has a GF Score™ of 12/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Bonyf NV's Return-on-Tangible-Equity compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Bonyf NV ranks #452 out of 759 companies for Return-on-Tangible-Equity. This places Bonyf NV in the lower half of its industry. The industry median Return-on-Tangible-Equity is 4.02. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Medical Devices & Instruments company?
The median Return-on-Tangible-Equity among Medical Devices & Instruments companies is 4.02, based on 759 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Bonyf NV and its competitors. For the Medical Devices & Instruments industry, the median Return-on-Tangible-Equity is 4.02 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bonyf NV's current Return-on-Tangible-Equity is -1.39%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bonyf NV stock overvalued right now?
Based on GuruFocus' analysis, Bonyf NV (XPAR:MLBON) is currently considered Possible Value Trap. The stock's GF Value™ is €8.61, compared to a current price of €2.48 — trading 71.2% below its estimated fair value. The current Return-on-Tangible-Equity is -1.39%. Bonyf NV's overall GF Score™ is 12/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Bonyf NV (XPAR:MLBON), the current Return-on-Tangible-Equity is -1.39% as of Dec. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bonyf NV (XPAR:MLBON) Overvalued in 2026?
Based on GuruFocus' analysis, Bonyf NV stock appears to be undervalued.
The current stock price of €2.48 is trading 71.2% below its estimated GF Value™ of €8.61.
GuruFocus considers Bonyf NV to be Possible Value Trap.
Key valuation signals for XPAR:MLBON:
Return-on-Tangible-Equity: -1.39%
GF Value™: €8.61 vs. price of €2.48 (71.2% below fair value)
No single metric tells the full story. See the XPAR:MLBON stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bonyf NV specializes in developing, producing and selling cutting-edge oral & dental care products. It is a forward-thinking company committed to revolutionizing oral care through innovation and research.
12GF Score
Get the complete analysis for XPAR:MLBON
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XPAR:MLBON has been successfully added to your 
